Vaccination with human induced pluripotent stem cells creates an antigen-specific immune response against HIV-1 gp160

Yoshizaki, Shinji; Nishi, Mayuko; Kondo, Asami; Kojima, Yoshitsugu; Yamamoto, Naoki; Ryo, Akihide

doi:10.3389/fmicb.2011.00027

Cited by 4 publications

(1 citation statement)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our RNA‐sequencing results showed that cancer cells and ESCs/iPSCs share several tumor‐associated antigens. iPSC‐based vaccines can induce antitumor immunity [7, 35–37]. Autologous iPSCs can provide more accurate and representative tumor‐related antigens [38], thus opening up new possibilities [14, 39, 40].…”

Section: Discussionmentioning

confidence: 99%

Evaluation of the safety and efficiency of cytotoxic T cell therapy sensitized by tumor antigens original from T‐ALL‐iPSC in vivo

Li,

Zhou,

Wang

et al. 2023

Cancer Innovation

View full text Add to dashboard Cite

BackgroundSince RNA sequencing has shown that induced pluripotent stem cells (iPSCs) share a common antigen profile with tumor cells, cancer vaccines that focus on iPSCs have made promising progress in recent years. Previously, we showed that iPSCs derived from leukemic cells of patients with primary T cell acute lymphoblastic leukemia (T‐ALL) have a gene expression profile similar to that of T‐ALL cell lines.MethodsMice with T‐ALL were treated with dendritic and T (DC‐T) cells loaded with intact and complete antigens from T‐ALL‐derived iPSCs (T‐ALL‐iPSCs). We evaluated the safety and antitumor efficiency of autologous tumor‐derived iPSC antigens by flow cytometry, cytokine release assay, acute toxicity experiments, long‐term toxicity experiments, and other methods.ResultsOur results indicate that complete tumor antigens from T‐ALL‐iPSCs could inhibit the growth of inoculated tumors in immunocompromised mice without causing acute and long‐term toxicity.ConclusionT‐ALL‐iPSC‐based treatment is safe and can be used as a potential strategy for leukemia immunotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluation of the safety and efficiency of cytotoxic T cell therapy sensitized by tumor antigens original from T‐ALL‐iPSC in vivo

Li,

Zhou,

Wang

et al. 2023

Cancer Innovation

View full text Add to dashboard Cite

show abstract

Induced pluripotent stem cell research: A revolutionary approach to face the challenges in drug screening

et al. 2012

View full text Add to dashboard Cite

Discovery of induced pluripotent stem (iPS) cells in 2006 provided a new path for cell transplantation and drug screening. The iPS cells are stem cells derived from somatic cells that have been genetically reprogrammed into a pluripotent state. Similar to embryonic stem (ES) cells, iPS cells are capable of differentiating into three germ layers, eliminating some of the hurdles in ES cell technology. Further progress and advances in iPS cell technology, from viral to non-viral systems and from integrating to non-integrating approaches of foreign genes into the host genome, have enhanced the existing technology, making it more feasible for clinical applications. In particular, advances in iPS cell technology should enable autologous transplantation and more efficient drug discovery. Cell transplantation may lead to improved treatments for various diseases, including neurological, endocrine, and hepatic diseases. In studies on drug discovery, iPS cells generated from patient-derived somatic cells could be differentiated into specific cells expressing specific phenotypes, which could then be used as disease models. Thus, iPS cells can be helpful in understanding the mechanisms of disease progression and in cell-based efficient drug screening. Here, we summarize the history and progress of iPS cell technology, provide support for the growing interest in iPS cell applications with emphasis on practical uses in cell-based drug screening, and discuss some challenges faced in the use of this technology.

show abstract

Mammalian cell cultures as models for Mycobacterium tuberculosis –human immunodeficiency virus (HIV) interaction studies: A review

Chingwaru

Glashoff

Vidmar

et al. 2016

Asian Pacific Journal of Tropical Medicine

View full text Add to dashboard Cite

Mycobacterium tuberculosis and human immunodeficiency virus (HIV) co-infections have remained a major public health concern worldwide, particularly in Southern Africa. Yet our understanding of the molecular interactions between the pathogens has remained poor due to lack of suitable preclinical models for such studies. We reviewed the use, this far, of mammalian cell culture models in HIV-MTB interaction studies. Studies have described the use of primary human cell cultures, including (1) monocyte-derived macrophage (MDM) fractions of peripheral blood mononuclear cell (PBMC), alveolar macrophages (AM), (2) cell lines such as the monocyte-derived macrophage cell line (U937), T lymphocyte cell lines (CEMx174, ESAT-6-specific CD4(+) T-cells) and an alveolar epithelial cell line (A549) and (3) special models such as stem cells, three dimensional (3D) or organoid cell models (including a blood-brain barrier cell model) in HIV-MTB interaction studies. The use of cell cultures from other mammals, including: mouse cell lines [macrophage cell lines RAW 264.7 and J774.2, fibroblast cell lines (NIH 3T3, C3H clones), embryonic fibroblast cell lines and T-lymphoma cell lines (S1A.TB, TIMI.4 and R1.1)]; rat (T cells: Rat2, RGE, XC and HH16, and alveolar cells: NR8383) and primary guinea pigs derived AMs, in HIV-MTB studies is also described. Given the spectrum of the models available, cell cultures offer great potential for host-HIV-MTB interactions studies.

show abstract

Vaccination with human induced pluripotent stem cells creates an antigen-specific immune response against HIV-1 gp160

Cited by 4 publications

References 28 publications

Evaluation of the safety and efficiency of cytotoxic T cell therapy sensitized by tumor antigens original from T‐ALL‐iPSC in vivo

Evaluation of the safety and efficiency of cytotoxic T cell therapy sensitized by tumor antigens original from T‐ALL‐iPSC in vivo

Induced pluripotent stem cell research: A revolutionary approach to face the challenges in drug screening

Mammalian cell cultures as models for Mycobacterium tuberculosis –human immunodeficiency virus (HIV) interaction studies: A review

Contact Info

Product

Resources

About